Abstract ISI
 (2022)

Phase 1/ 2 study of quavonlimab (Qmab) plus pembrolizumab (pembro) in patients (pts) with advanced melanoma that progressed on a PD-1/PD-L1 inhibitor

Deva, S; Mackiewicz J.; Dalle S.; Gogas, H; Lugowska, I; Berrocal A.; Menzies A.M.; Maio, M; Nagrial, A; Eizmendi, KM; Grob J.J.; Caglevic C.; Lyle, M; Martin-Liberal, J; Altura, R; et. al.